BRAF and neoplasm: Targeting BCL‐xL‐/BCL‐2 could sensitize tumour‐resistant cells to EGFR inhibitors,21 or result in the inhibition of actin remodelling molecules counteracting adaptive resistance to BRAF inhibitors in melanoma.59